Glenmark obtains DCGI nod for clinical study of its GRC 54276 molecule

By Akshay Kedari  | Date: 2022-04-12

Glenmark obtains DCGI nod for clinical study of its GRC 54276 molecule

Glenmark Pharmaceuticals Limited has reportedly received approval from the DCGI (Drug Controller General of India) to perform phase 1 clinical trials of its novel molecule for advanced solid tumor patients.

Glenmark Specialty SA obtained the DCGI nod for GRC 54276, the company’s novel small molecule which is an HPK1 (hematopoietic progenitor kinase 1) inhibitor.

For those unaware, GRC 54276 is one of the several novel molecules from the company’s Innovative Medicines Group which specializes in the development of advanced molecular entities for crucial unsatisfied medical needs.

Speaking about the molecule, Glenmark stated that GRC 54276 has showcased the ability to eliminate tumour cells in preclinical studies through combination with checkpoint inhibitors as well as a single agent, further marking it as a key target in immuno-oncology.

The study will assess the tolerability and safety of GRC 54276 in combination with checkpoint inhibitors and as a monotherapy in patients with Hodgkin's lymphoma and advanced solid tumours.

Glenmark cited that it will commence Phase 1 clinical trial in India by June this year and intends to file an Investigational New Drug (IND) application in the United States as well as a clinical trial application in Europe to initiate a global clinical study program.

Glenn Saldanha, the Chairman & Managing Director of Glenmark Pharmaceuticals, believes that the clinical study approval of the novel molecule, which is a part of the newly established Innovative Medicines Group within the organization, will strengthen the company’s growth abilities of innovative clinical research and allow it to offer comprehensive cancer treatment solutions.

It is worth noting that Glenmark has a presence across generics, specialty, and OTC businesses. The company focuses on crucial therapeutic areas of oncology, dermatology, and respiratory. The company has nearly 10 manufacturing facilities across four continents and operates in more than 80 countries.

Source credits:

https://www.business-standard.com/article/pti-stories/glenmark-receives-dcgi-nod-to-conduct-clinical-trials-of-its-molecule-on-cancer-patients-122041100273_1.html

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More >>

More News By Akshay Kedari

Bayer sells environmental science biz to Indian firm for $13.5 million

Bayer sells environmental science biz to Indian firm for $13.5 million

By Akshay Kedari

German multinational pharmaceutical and biotechnology company, Bayer CropScience recently stated that its board has given the go-ahead for selling its Environmental Science Business to 2022 ES Discovery India, a private Indian company. The deal wi...

Stockly to raise another $12M to expand its operations & employee base

Stockly to raise another $12M to expand its operations & employee base

By Akshay Kedari

French-based software startup, Stockly is reportedly raising another $12 million (€12 million) in a Series A round from Daphni, Eurazeo, and several other business angels. Apparently, the firm pools together the inventory of several e-commerc...

Alipay+ allies with Asian E-Wallets to boost cashless travel in South Korea

Alipay+ allies with Asian E-Wallets to boost cashless travel in South Korea

By Akshay Kedari

Amidst rising efforts for promoting cashless travel, prominent mobile payment providers in Asia have recently announced an integration of the cross-border digitalized payment solutions from Alipay+ in South Korea. With this move, users of e-wallet...

Seracle, Sumsub partner for offering enhanced KYC protocols and cybersecurity

Seracle, Sumsub partner for offering enhanced KYC protocols and cybersecurity

By Akshay Kedari

Sumsub will assist Seracle in building an innovative blockchain ecosystem Sumsub will offer enhanced security to Seracle at a time when losses due to cryptocurrency thefts have increased by about 60% to $1.9 billion Seracle, a global blockc...

CATL unveils new Module to Bracket tech for heavy-duty electric trucks

CATL unveils new Module to Bracket tech for heavy-duty electric trucks

By Akshay Kedari

CATL, a Chinese battery manufacturer and technology company, has reportedly introduced a new battery technology known as Module to Bracket (MTB) for heavy-duty electric trucks. As per reliable sources, the MTB technology deploys the battery module...